Compounds > celecoxib

celecoxib and su 11248

celecoxib has been researched along with su 11248 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Freĭdlin, IS; Kiseleva, EP; Kuznetsova, SA; Liamina, IV; Starikova, EA1
Alsop, DC; Atkins, MB; Bahamon, B; Bhatt, RS; Goldberg, SN; Mier, JW; O'Neill, A; Signoretti, S; Wang, X; Wood, CG; Zhang, L1
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J1
Chu, Y; Guo, J; Hu, X; Wang, G; Zhao, Q1

Reviews

1 review(s) available for celecoxib and su 11248

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for celecoxib and su 11248

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
[Effect of sutent and celecoxib on the properties of endothelial cells in vitro].
    Voprosy onkologii, 2009, Volume: 55, Issue:5

    Topics: 5'-Nucleotidase; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Celecoxib; Cell Movement; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Indoles; Pyrazoles; Pyrroles; Sulfonamides; Sunitinib

2009
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
    British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Indoles; Kidney Neoplasms; Mice; Pyrazoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays

2013
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
    Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:3

    Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib

2016
Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma.
    Oncotarget, 2017, Jan-03, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasm Transplantation; Pyrroles; STAT3 Transcription Factor; Sunitinib; T-Lymphocytes, Regulatory

2017